Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial
Age and Ageing · 03.08.2026 · 55 (8)
DOI: 10.1093/ageing/afag224 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, online erschienen am 03.08.2026. Verfasst von Sang-Hyup Lee und 21 weiteren Autor:innen. Beteiligte Einrichtung: Yonsei University College of Medicine, Division of Cardiology, Seodaemun-gu, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Atrial Fibrillation, Drug-Eluting Stents, Percutaneous Coronary Intervention, Clopidogrel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Cardiovascular Research Center, National Research Foundation of Korea.
Abstract (Originalsprache)
Background
Evidence for non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy for older patients with atrial fibrillation (AF) and drug-eluting stents is lacking.
Objectives
We aimed to evaluate the safety and efficacy of NOAC monotherapy in older AF patients with drug-eluting stents.
Methods
This is a secondary analysis of the ADAPT AF-DES randomised trial comparing NOAC monotherapy with combination therapy with NOAC plus clopidogrel in patients with AF and drug-eluting stents. Patients were stratified by age (≥75 years and <75 years). Apixaban or rivaroxaban was used as the NOAC. The primary endpoint was a net adverse clinical event at 1 year after randomisation, defined as a composite of all-cause death, myocardial infarction, stent thrombosis, stroke, systemic embolism or major or clinically relevant non-major bleeding defined by the International Society on Thrombosis and Haemostasis criteria.
Results
Among 960 patients included in the ADAPT AF-DES trial, 376 (39.2%) patients were aged ≥75 years. In patients aged ≥75 years, the incidence of the primary endpoint was lower in the NOAC monotherapy group (9.8% vs. 22.3%; adjusted hazard ratio, 0.37; 95% confidence interval, 0.21–0.66; P < .001) than in the combination therapy group. In contrast, the incidences did not differ between treatment strategies in patients aged <75 years. The interaction between age groups and strategy groups did not reach statistical significance (P for interaction = .095). The reduction in major or clinically relevant non-major bleeding with NOAC monotherapy was consistent across age groups. In contrast, the benefit of NOAC monotherapy in major adverse cardiac and cerebrovascular events was more pronounced in patients aged ≥75 years, with a statistically significant interaction.
Conclusions
In this post hoc analysis, NOAC monotherapy was associated with a lower risk of net adverse clinical events, specifically within the older age subgroup. Tailored approach regarding age and individual ischaemic risk may be needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yonsei University College of Medicine, Division of Cardiology, Seodaemun-gu, Seoul, Republic of Korea.
- Kosin University Gospel Hospital, Division of Cardiology, Busan, Republic of Korea.
- Kangwon National University Hospital, Division of Cardiology, Chuncheon-si, Gangwon-do, Republic of Korea.
- Inje University Sanggye Paik Hospital, Division of Cardiology, Seoul, Nowon-gu, Republic of Korea.
- Chungbuk National University Hospital, Division of Cardiology, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
- CHA University Bundang Medical Center, Division of Cardiology, Seongnam-si, Gyeonggi-do, Republic of Korea.
ORCID-Profile: Jaemin Shim, Ji-Yong Jang, Yong-Joon Lee, Hee Tae Yu, Byeong-Keuk Kim, Young-Guk Ko, Myeong-Ki Hong, Hui-Nam Pak, Jung-Sun Kim
Förderung
- Cardiovascular Research Center, National Research Foundation of Korea
Zitieren
APA
Lee, S. H., Kim, S. J., Her, A. Y., Cho, B. R., Kim, G. S., Kwon, T. G., Lim, S. W., Shim, J., Jang, J. Y., Lee, Y. J., Lee, S. J., Yu, H. T., Hong, S. J., Ahn, C. M., Kim, B. K., Ko, Y. G., Choi, D., Hong, M. K., Jang, Y., …, & Heo, J. H. (2026). Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial. Age and Ageing, 55(8). https://doi.org/10.1093/ageing/afag224
Vancouver
Lee SH, Kim SJ, Her AY, Cho BR, Kim GS, Kwon TG, et al. Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial. Age and Ageing. 2026;55(8). doi:10.1093/ageing/afag224
BibTeX
@article{Lee2026,
author = {Lee, Sang-Hyup and Kim, Soo-Jin and Her, Ae-Young and Cho, Byung-Ryul and Kim, Gwang-Sil and Kwon, Taek-Geun and Lim, Sang-Wook and Shim, Jaemin and Jang, Ji-Yong and Lee, Yong-Joon and Lee, Seung-Jun and Yu, Hee Tae and Hong, Sung-Jin and Ahn, Chul-Min and Kim, Byeong-Keuk and Ko, Young-Guk and Choi, Donghoon and Hong, Myeong-Ki and Jang, Yangsoo and Pak, Hui-Nam and Kim, Jung-Sun and Heo, Jung Ho},
title = {Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial},
journal = {Age and Ageing},
year = {2026},
volume = {55},
number = {8},
doi = {10.1093/ageing/afag224}
}
EUVIMED